Sanofi (NASDAQ:SNY) Shares Sold by Royal Bank of Canada

Royal Bank of Canada cut its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 2.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,392,488 shares of the company's stock after selling 51,511 shares during the quarter. Royal Bank of Canada owned 0.09% of Sanofi worth $115,391,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Abel Hall LLC raised its holdings in Sanofi by 1.8% during the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company's stock worth $530,000 after purchasing an additional 194 shares during the last quarter. Providence Capital Advisors LLC raised its holdings in Sanofi by 0.4% during the fourth quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company's stock worth $2,653,000 after purchasing an additional 201 shares during the last quarter. Keudell Morrison Wealth Management raised its holdings in Sanofi by 1.7% during the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company's stock worth $624,000 after purchasing an additional 217 shares during the last quarter. Bailard Inc. raised its holdings in Sanofi by 1.4% during the fourth quarter. Bailard Inc. now owns 16,359 shares of the company's stock worth $789,000 after purchasing an additional 220 shares during the last quarter. Finally, Bessemer Group Inc. raised its holdings in Sanofi by 59.8% during the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after purchasing an additional 242 shares during the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SNY has been the subject of several recent research reports. BNP Paribas initiated coverage on Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target for the company. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. The Goldman Sachs Group initiated coverage on Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 price target for the company. Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $63.33.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $52.28 on Tuesday. Sanofi has a 52 week low of $45.80 and a 52 week high of $60.12. The company has a market cap of $132.07 billion, a P/E ratio of 21.00, a P/E/G ratio of 1.01 and a beta of 0.55. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The business has a fifty day simple moving average of $53.25 and a 200-day simple moving average of $51.88.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The firm had revenue of $10.41 billion for the quarter, compared to analysts' expectations of $9.79 billion. During the same quarter last year, the firm earned $1.78 earnings per share. The firm's revenue for the quarter was down 11.0% compared to the same quarter last year. Equities research analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be issued a $2.0369 dividend. The ex-dividend date is Friday, May 9th. This represents a yield of 3.1%. This is a boost from Sanofi's previous annual dividend of $1.48. Sanofi's dividend payout ratio (DPR) is presently 57.14%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.